Toby Maher, ERS 2019 – Pirfenidone in Patients with Progressive Fibrosing Unclas1
Автор: Bolton Pulmonary Fibrosis Support Group
Загружено: 2021-10-28
Просмотров: 27
Professor Toby Maher is a consultant respiratory physician and is based at Royal Brompton Hospital. He also holds the positions of honorary senior lecturer at the National Heart and Lung Institute, Imperial College London, and honorary senior research associate at University College London. In this video discusses the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD).
Questions
1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05)
2. What is the current standard of care for patients with progressive fibrosing uILD? (0:44)
3. Could you tell us a little about the design and findings of the recent study investigating pirfenidone in patients with progressive fibrosing uILD? (1:11)
4. Which patients are most likely to respond to this treatment approach? (1:55)
5. What further studies are planned? (2:33)
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
